Research
Cellular
Caution is advised when initiating GLP-1 agonist therapy in HIV patients taking protease inhibitors.
Healthcare providers should monitor HIV patients on protease inhibitors closely when starting GLP-1 agonists.
StrongQualifiesmedium confidence
Extra caution should be warranted when initiating GLP-1 agonist therapy in people with HIV taking protease inhibitors who have pre-existing risk factors for heart rate variability.
Why this rating
Based on clinical observations mentioned in the abstract.
Source
<scp>GLP</scp>‐1 agonists for people living with <scp>HIV</scp> and obesity, is there a potential?
Leena Zino et al. · HIV Medicine · 2023
DOI 10.1111/hiv.13521
case_studyCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →